Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Infectious Complications in Autoimmune Hemolytic Anemia: A Multi-Center Italian Experience

Nicolo Rampi, Bruno Fattizzo, Nicola Cecchi, Edoardo Tamellini, Francesca Morelli, Ilaria Tanasi, Maria Di Perna, Simona Raso, Angelo Gardellini, Dorela Lame, Marica Laurino, Olga Mulas, Antonello Rana, Paola Bianchi, Wilma Barcellini

Blood (2023) 142 (Supplement 1): 5205.

https://doi.org/10.1182/blood-2023-182224

Published: 2023

Journal Articles

Association of Hypomethylating Agents + Venetoclax in the Real-Life Treatment of Myeloproliferative Neoplasms in Blastic Phase

Blood (2023) 142 (Supplement 1): 1842.

https://doi.org/10.1182/blood-2023-190091

Published: 2023

Journal Articles

Patients' Perception of Usability and Utility of a Digital Health Tool for Electronic Patient-Reported Outcomes Monitoring in Real-Life Hematology Practice: Evidence from the Gimema-Alliance Platform

Blood (2023) 142 (Supplement 1): 3714.

https://doi.org/10.1182/blood-2023-180574

Published: 2023

Journal Articles

On the Children Side. Overview of 194 Outcomes from Gimema Registry of Conception/Pregnancy in Chronic Myeloid Leukemia (CML)

Blood (2023) 142 (Supplement 1): 3178.

https://doi.org/10.1182/blood-2023-188305

Published: 2023

Journal Articles

Increase of Arterial Stiffness in Patients with Polycythemia Vera

Olga Mulas, Giovanni Caocci, Alessandro Sestu, Carla Vargiu, Ludovica Corda, Salvatore Chessa, Francesca Pittau, Brunella Mola, Alessandro Costa, Giorgio La Nasa, Angelo Scuteri

Blood (2023) 142 (Supplement 1): 6430.

https://doi.org/10.1182/blood-2023-187123

Published: 2023

Journal Articles

Thrombotic and Infectious Complications in Patients with Autoimmune Hemolytic Anemia: A Multicenter Observational Study

Bruno Fattizzo, Nicola Cecchi, Edoardo Tamellini, Francesca Morelli, Ilaria Tanasi, Maria Di Perna, Simona Raso, Angelo Gardellini, Dorela Lame, Marica Laurino, Olga Mulas, Antonello Rana, Paola Bianchi, Wilma Barcellini

Blood (2022) 140 (Supplement 1): 2451–2453.

https://doi.org/10.1182/blood-2022-167199

Published: 2022

Journal Articles

Choice of Tyrosine Kinase Inhibitor and Early Events during the First Year of Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) Patients with Concomitant Diabetes: A "Campus CML" Study

Blood (2022) 140 (Supplement 1): 3920–3922.

https://doi.org/10.1182/blood-2022-164790

Published: 2022

Journal Articles

Permanent Discontinuation of Tyrosine Kinase Inhibitor Frontline Therapy in Patients with Chronic Phase Chronic Myeloid Leukemia Patients during the First 36 Months of Treatment: A "Campus CML" Study

Blood (2022) 140 (Supplement 1): 3906–3907.

https://doi.org/10.1182/blood-2022-170415

Published: 2022

Journal Articles

Association of Hypometilating Agents (HMA) + Venetoclax (VEN) in the Treatment of Myeloproliferative Neoplasms in Blastic Phase (MPN-BP) and Acute Leukemias Evolved from Myelodysplastic Syndromes (AML-MDS) Already Treated with Azacytidine

Blood (2022) 140 (Supplement 1): 6176–6178.

https://doi.org/10.1182/blood-2022-167334

Published: 2022

Journal Articles

Should be a Third Dose of BNT162b2 mRNA COVID-19-Vaccine Administered in Patients with Myelofibrosis Under Ruxolitinib?

Giovanni Caocci, Olga Mulas, Daniela Mantovani, Alessandro Costa, Andrea Galizia, Luca Barabino, Marianna Greco, Roberta Murru, Giorgio La Nasa

Blood (2021) 138 (Supplement 1): 2573.

https://doi.org/10.1182/blood-2021-146381

Published: 2021

Journal Articles

Analysis of Early Events during the First Year of Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Phase - Chronic Myeloid Leukemia: A "Campus CML" Study

Blood (2021) 138 (Supplement 1): 1487.

https://doi.org/10.1182/blood-2021-149780

Published: 2021

Journal Articles

Pro-Inflammatory and Pro-Oxidative Changes during Nilotinib Treatment in CML Patients: Results of a Prospective Multicenter Front-Line TKIs Study (KIARO Study)

Anna Sicuranza, Ilaria Ferrigno, Elisabetta Abruzzese, Alessandra Iurlo, Sara Galimberti, Antonella Gozzini, Luigiana Luciano, Fabio Stagno, Antonella Russo Rossi, Nicola Sgherza, Daniele Cattaneo, Corrado Zuanelli Brambilla, Cristina Marzano, Carmen Fava, Olga Mulas, Emanuele Cencini, Alessandro Gozzetti, Luca Puccetti, Monica Bocchia

Blood (2021) 138 (Supplement 1): 1479.

https://doi.org/10.1182/blood-2021-152530

Published: 2021

Journal Articles

Low Cholesterol, Low-Density Lipoprotein (LDL) and Triglycerides Plasma Levels Are Associated with Lower Risk of Arterial Occlusive Events in Chronic Myeloid Leukemia Patients Treated with Nilotinib

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-134496

Published: 2020

Journal Articles

Predictive Factors for Overall Survival in Chronic Myeloid Leukemia Patients: An Analysis By the Gimema Cml Italian Study

Giorgina Specchia, MD, Patrizia Pregno, Massimo Breccia, MD, Chiara Monagheddu, Fausto Castagnetti, MDPhD, Massimiliano Bonifacio, MD, Mario Tiribelli, MD, Fabio Stagno, MD PhD, Giovanni Caocci, MD, Bruno Martino, MD, Luigiana Luciano, MD, Michele Pizzuti, MD, Antonella Gozzini, MD, Anna Rita Scortechini, MD, Francesco Albano, Micaela Bergamaschi, MD, Isabella Capodanno, MD, Andrea Patriarca, MD, Carmen Fava, Giovanna Rege Cambrin, MDPhD, Federica Sorà, MD, Sara Galimberti, MD PhD, Monica Bocchia, Gianni Binotto, MD, Giovanni Reddiconto, Attilio Guarini, MD, Alessandro Maggi, Grazia Sanpaolo, MD, Maria Stella De Candia, Valentina Giai, MD PhD, Elisabetta Abruzzese, MD, Maria Cristina Miggiano, MD, Franca Falzetti, MD, Gaetano La Barba, Giuseppe Pietrantuono, Anna Guella, MD, Luciano Levato, MD, Olga Mulas, Fabio Saccona, Gianantonio Rosti, MD, Pellegrino Musto, MD, Francesco Di Raimondo, MD, Fabrizio Pane, MD, Robin Foà, MD, Michele Baccarani, MD, Giovannino Ciccone, Giuseppe Saglio, MD PhD

Blood (2020) 136 (Supplement 1): 47–48.

https://doi.org/10.1182/blood-2020-139307

Published: 2020

Journal Articles

Peripheral Blood CD26+ Leukemia Stem Cells Monitoring in Chronic Myeloid Leukemia Patients from Diagnosis to Response to TKIs: Interim Results of a Multicenter Prospective Study (PROSPECTIVE FLOWERS)

Blood (2020) 136 (Supplement 1): 45–46.

https://doi.org/10.1182/blood-2020-139306

Published: 2020

Journal Articles

Metabolomics Profile of Patients with Chronic Myeloid Leukemia and Cardiovascular Adverse Events after Treatment with Tyrosine Kinase Inhibitors

Giovanni Caocci, MD, Martino Deidda, Antonio Noto, Christian Cadeddu, Marianna Greco, Maria Pina Simula, Olga Mulas, Daniele Cocco, Claudia Fattuoni, Giuseppe Mercuro, Giorgio La Nasa

Blood (2019) 134 (Supplement_1): 4144.

https://doi.org/10.1182/blood-2019-124323

Published: 2019

Journal Articles

Increased Incidence of Infection in Patients with Myelofibrosis and Transfusion-Associated Iron Overload: A Monocentric Experience

Giovanni Caocci, MD, Maria Pina Simula, Silvia Ghiani, Olga Mulas, Giorgia Mainas, Sandra Atzeni, Martina Pettinau, Emilio Usala, Giorgio La Nasa, MD

Blood (2019) 134 (Supplement_1): 4186.

https://doi.org/10.1182/blood-2019-122006

Published: 2019

Journal Articles

Arterial Occlusive Events in Chronic Myeloid Leukemia Patients Treated with Ponatinib in the Real-Life Practice: Prophylaxis and Identification of Risk Factors

Blood (2018) 132 (Supplement 1): 3006.

https://doi.org/10.1182/blood-2018-99-111502

Published: 2018

Journal Articles

Persistence of Residual Circulating CD26+ Leukemia Stem Cells in Chronic Myeloid Leukemia Patients in Treatment Free Remission

Blood (2017) 130 (Supplement 1): 249.

https://doi.org/10.1182/blood.V130.Suppl_1.249.249

Published: 2017

Journal Articles

Peripheral Blood Flow-Cytometry Chronic Myeloid Leukemia Stem Cells Detection and Quantification during Tyrosine Kinase Inhibitors Therapy

Blood (2016) 128 (22): 942.

https://doi.org/10.1182/blood.V128.22.942.942

Published: 2016

NARROW

Infectious Complications in Autoimmune Hemolytic Anemia: A Multi-Center Italian Experience

Association of Hypomethylating Agents + Venetoclax in the Real-Life Treatment of Myeloproliferative Neoplasms in Blastic Phase

Patients' Perception of Usability and Utility of a Digital Health Tool for Electronic Patient-Reported Outcomes Monitoring in Real-Life Hematology Practice: Evidence from the Gimema-Alliance Platform

On the Children Side. Overview of 194 Outcomes from Gimema Registry of Conception/Pregnancy in Chronic Myeloid Leukemia (CML)

Increase of Arterial Stiffness in Patients with Polycythemia Vera

Thrombotic and Infectious Complications in Patients with Autoimmune Hemolytic Anemia: A Multicenter Observational Study

Choice of Tyrosine Kinase Inhibitor and Early Events during the First Year of Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) Patients with Concomitant Diabetes: A "Campus CML" Study

Permanent Discontinuation of Tyrosine Kinase Inhibitor Frontline Therapy in Patients with Chronic Phase Chronic Myeloid Leukemia Patients during the First 36 Months of Treatment: A "Campus CML" Study

Association of Hypometilating Agents (HMA) + Venetoclax (VEN) in the Treatment of Myeloproliferative Neoplasms in Blastic Phase (MPN-BP) and Acute Leukemias Evolved from Myelodysplastic Syndromes (AML-MDS) Already Treated with Azacytidine

Should be a Third Dose of BNT162b2 mRNA COVID-19-Vaccine Administered in Patients with Myelofibrosis Under Ruxolitinib?

Analysis of Early Events during the First Year of Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Phase - Chronic Myeloid Leukemia: A "Campus CML" Study

Pro-Inflammatory and Pro-Oxidative Changes during Nilotinib Treatment in CML Patients: Results of a Prospective Multicenter Front-Line TKIs Study (KIARO Study)

Low Cholesterol, Low-Density Lipoprotein (LDL) and Triglycerides Plasma Levels Are Associated with Lower Risk of Arterial Occlusive Events in Chronic Myeloid Leukemia Patients Treated with Nilotinib

Predictive Factors for Overall Survival in Chronic Myeloid Leukemia Patients: An Analysis By the Gimema Cml Italian Study

Peripheral Blood CD26+ Leukemia Stem Cells Monitoring in Chronic Myeloid Leukemia Patients from Diagnosis to Response to TKIs: Interim Results of a Multicenter Prospective Study (PROSPECTIVE FLOWERS)

Metabolomics Profile of Patients with Chronic Myeloid Leukemia and Cardiovascular Adverse Events after Treatment with Tyrosine Kinase Inhibitors

Increased Incidence of Infection in Patients with Myelofibrosis and Transfusion-Associated Iron Overload: A Monocentric Experience

Arterial Occlusive Events in Chronic Myeloid Leukemia Patients Treated with Ponatinib in the Real-Life Practice: Prophylaxis and Identification of Risk Factors

Persistence of Residual Circulating CD26+ Leukemia Stem Cells in Chronic Myeloid Leukemia Patients in Treatment Free Remission

Peripheral Blood Flow-Cytometry Chronic Myeloid Leukemia Stem Cells Detection and Quantification during Tyrosine Kinase Inhibitors Therapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only